The Medicare GLP-1 Bridge: A Patient Guide to the July 1, 2026 Launch

Wednesday July 1, 2026 marks the first time Medicare will help pay for GLP-1 weight-loss drugs prescribed for obesity alone (no diabetes, no heart disease, no other approved indication required). The Medicare GLP-1 Bridge is a Centers for Medicare and Medicaid Services demonstration program that gives eligible Part D beneficiaries access to four GLP-1 medications at a $50 monthly copay through December 31, 2027.

The four drugs are Foundayo (oral orforglipron tablets, Eli Lilly), Wegovy injection (semaglutide, Novo Nordisk), Wegovy oral tablets in 1.5, 4, 9, and 25 mg strengths (also semaglutide), and Zepbound KwikPen (tirzepatide single-dose pen, Eli Lilly). Humana, the company that already runs Medicare's low-income drug-access program, handles all the paperwork and pays the pharmacy directly.

You qualify if you are enrolled in an eligible Medicare Part D plan, have never used a GLP-1 through Part D before, do not have type 2 diabetes, moderate-to-severe sleep apnea, or MASH (since those conditions are already covered through standard Part D), and meet one of three body mass index (BMI) thresholds with the right paired condition. The thresholds are walked through below. This piece is the practical guide: who qualifies, what is covered, how to apply, what it costs, and what happens after the Bridge ends.

Medicare has historically excluded weight-loss drugs from Part D coverage. The original 2003 Medicare Modernization Act language barred Part D plans from covering drugs prescribed for weight loss, with rare exceptions for diabetes, cardiovascular risk, and a few other approved indications. As GLP-1 receptor agonists (semaglutide, tirzepatide) became standard obesity care for the under-65 population through 2024 and 2025, Medicare beneficiaries were left out.

The Bridge is a CMS demonstration project that breaks the exclusion in a controlled way. It is not a permanent benefit. It runs from July 1, 2026 through December 31, 2027 as a short-term program, and it operates outside of the regular Part D benefit (Part D plan sponsors do not carry risk for these drugs under the Bridge). Once the Bridge expires, the broader BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) takes over starting January 1, 2027 in Medicare Part D with a permanent obesity-coverage framework. The Bridge is the testing ground for the BALANCE Model that follows.

In plain terms: the Bridge gets people on the drugs starting Wednesday at $50 per month, while CMS works out the long-term policy details for the program that replaces it.

Eligibility runs through three body mass index (BMI) tiers, with a paired condition required for the lower two tiers.

Tier 1: BMI of 35 or higher. No paired condition needed. This covers patients with class II or class III obesity.

Tier 2: BMI of 30 to 34.9. You also need a documented diagnosis of one of three conditions: heart failure (any severity), uncontrolled hypertension (high blood pressure not adequately managed on current medications), or chronic kidney disease (any stage).

Tier 3: BMI of 27 to 29.9. You need a documented diagnosis of one of four conditions: pre-diabetes (elevated blood sugar not yet meeting the type 2 diabetes threshold), prior heart attack (myocardial infarction), prior stroke, or symptomatic peripheral artery disease.

The key procedural point: BMI is recorded at the time you start GLP-1 therapy, not at the time you apply. If your BMI drops below the threshold while you are on the drug, you stay covered. The prescriber attests to your starting BMI on the prior-authorization form.

Note what is NOT a qualifying paired condition: type 2 diabetes (already covered through standard Part D), moderate-to-severe sleep apnea (Zepbound is FDA-approved for OSA and that prescription would go through standard Part D), and MASH (Wegovy was approved for MASH in February 2026 and is covered through standard Part D for that indication). The Bridge is specifically for obesity-only prescriptions that have not previously had Medicare coverage.

If you have one of three conditions, you do not use the Bridge. You use standard Part D coverage instead, because the same drugs are already covered for these indications.

Type 2 diabetes. Ozempic (semaglutide injection), Rybelsus (oral semaglutide for T2D, now sold as Ozempic Pill), Mounjaro (tirzepatide for T2D), and Trulicity (dulaglutide) are all standard Part D-covered drugs for type 2 diabetes. The Bridge does not apply, because your existing Part D plan already covers the prescription.

Moderate-to-severe obstructive sleep apnea (OSA). Zepbound received FDA approval for OSA in adults with obesity in late 2024, and that indication is covered through standard Part D. If your prescriber writes Zepbound for OSA, you use your regular Part D coverage. The Bridge applies only when Zepbound is written for chronic weight management without OSA.

Metabolic dysfunction-associated steatohepatitis (MASH). Wegovy was approved for MASH in adults without cirrhosis with moderate-to-advanced fibrosis in February 2026, and that indication is covered through standard Part D. The Bridge applies only when Wegovy is written for chronic weight management without MASH.

The distinction matters because the Bridge has tighter eligibility and lower copay ($50/month) than most Part D plans charge for GLP-1 prescriptions at standard formulary tiers. If you qualify for standard Part D coverage at a higher copay, the Bridge might still be the better option for you, but the prescriber and pharmacist need to know which pathway applies. Talk to both.

Four GLP-1 drugs are eligible under the Bridge.

Foundayo (orforglipron, Eli Lilly). Oral tablet, FDA-approved for chronic weight management in April 2026. Once-daily dosing. Foundayo is the only oral small-molecule GLP-1 in this list (semaglutide, tirzepatide, and the Wegovy tablet are all peptide drugs delivered orally only at the higher 25 mg dose).

Wegovy injection (semaglutide, Novo Nordisk). Subcutaneous injection, once-weekly. The 7.2 mg Wegovy HD strength is the highest available dose and reached the market in April 2026.

Wegovy tablets (oral semaglutide, Novo Nordisk). The Wegovy pill, FDA-approved for obesity in late 2025 and launched January 5, 2026. Available in 1.5 mg, 4 mg, 9 mg, and 25 mg once-daily tablets. The 25 mg dose is the labeled effective weight-loss strength; lower doses are titration steps.

Zepbound KwikPen (tirzepatide, Eli Lilly). Subcutaneous injection via the KwikPen single-dose autoinjector, once-weekly. Available in 2.5, 5, 7.5, 10, 12.5, and 15 mg strengths for chronic weight management.

The pricing is set by CMS through the Bridge structure. Pharmacies bill Humana (the central processor) for the wholesale acquisition cost of the drug, minus the $50 patient copay, plus a dispensing fee and any applicable sales tax. The pharmacy does not bill your Part D plan for these prescriptions. You pay $50 at the counter and that is it.

The monthly copay is $50 per 30-day supply. That is the only out-of-pocket cost for the drug under the Bridge.

What is not included in the $50: lab work the prescriber may order before starting the drug (CBC, comprehensive metabolic panel, HbA1c, lipid panel), office-visit copays for the prescribing physician, syringes or needles if your pharmacy does not include them, sharps disposal containers, and the cost of any second-opinion consultations. These items go through your standard Medicare coverage at whatever copay or coinsurance your plan applies.

For reference, the same drugs cost between $1,200 and $1,640 per month without insurance at the standard manufacturer list price. Under the Bridge, you pay a small fraction of that. The Bridge specifically does not bill your Part D plan or count against your Part D out-of-pocket spending; it is run as a separate program with separate financing.

One procedural note: if you are dual-eligible for Medicare and Medicaid, the Bridge does not change your state Medicaid coverage of GLP-1 drugs. Some states cover GLP-1s for obesity in their Medicaid programs and some do not. If your state Medicaid covers the prescription with a lower or zero copay, you use Medicaid first; the Bridge is for Medicare beneficiaries who do not have a lower-cost alternative.

The application happens in three steps and runs through your doctor and pharmacy, not directly through you.

Step 1: Doctor screens you for eligibility. Your prescribing physician confirms three things: you are enrolled in an eligible Part D plan, you have not previously received a GLP-1 through Part D, and you meet one of the three BMI-and-condition tiers. They also confirm you do not have type 2 diabetes, moderate-to-severe sleep apnea, or MASH (which would route the prescription through standard Part D instead).

Step 2: Doctor writes the prescription and sends it to your pharmacy. Use whichever pharmacy you typically use; the Bridge does not require a specific pharmacy network. Major chains (CVS, Walgreens, Rite Aid, Costco), independent pharmacies, and mail-order pharmacies are all participating.

Step 3: Pharmacy and doctor complete the prior authorization through Humana. Your pharmacy sends a prior-authorization request to your doctor (usually within 24 to 72 hours of receiving the prescription). The doctor fills out the form and faxes or electronically submits it to Humana, the program's central processor. Humana reviews the documentation, confirms eligibility, and authorizes the prescription. Once approved, the pharmacy can dispense the drug; you pay your $50 copay and pick it up.

Key procedural points: your prescriber does not need to be enrolled in Medicare to write a Bridge prescription (they just cannot be on the FDA's Preclusion List). The Bridge uses its own Bank Identification Number (BIN) and Processor Control Number (PCN) for pharmacy claims: BIN 028918, PCN MEDDGLP1BR. If a pharmacy is unfamiliar with the Bridge, those identifiers are how they bill the central processor instead of your regular Part D plan.

First-fill prior authorization is required. After the first fill is approved, subsequent monthly refills do not need a new prior authorization unless you switch drugs (see below).

Refills of the same drug at the same or adjusted dose do not require a new prior authorization. If your prescriber increases your Foundayo dose from one tablet strength to another, or your Wegovy injection from 2.4 mg to 7.2 mg, or your Zepbound KwikPen from 5 mg to 10 mg, those dose changes flow through the existing authorization.

Switching drugs does require a new prior authorization. If you start on Wegovy injection and your prescriber moves you to Zepbound KwikPen or Foundayo tablets, the pharmacy and prescriber file a new PA with Humana before the new prescription can be filled. Reasons for switching that Humana will accept include intolerance to the original drug (gastrointestinal side effects, injection-site reactions), insufficient weight-loss response, supply issues, or patient preference.

One important note: the Bridge is for chronic weight management only. If you stop the drug and want to restart later, you should be able to do so during the Bridge demonstration period (through December 31, 2027) as long as you still meet the eligibility criteria. After December 31, 2027, the Bridge ends and you transition to the BALANCE Model (see below) or to whatever Part D coverage your plan provides at that time.

Several things the Bridge is not.

It is not a permanent benefit. December 31, 2027 is the hard end date. After that, you transition to the BALANCE Model or to standard Part D coverage.

It does not cover compounded GLP-1s. The Bridge is for FDA-approved branded products only (Foundayo, Wegovy injection, Wegovy tablets, Zepbound KwikPen). Compounded semaglutide and tirzepatide from 503A or 503B pharmacies are not eligible.

It does not cover retatrutide, mazdutide, survodutide, or other investigational GLP-1s. These drugs are not yet FDA-approved for obesity, so they are not eligible for the Bridge. Retatrutide submission is expected in late 2026 with launch in 2027 to 2028.

It does not cover off-label use. If a prescriber writes a Bridge-eligible drug for an indication other than chronic weight management in a qualifying patient, the Bridge does not apply.

It does not retroactively cover previous prescriptions. Only fills from July 1, 2026 forward are eligible, and only first-time GLP-1 use through Part D qualifies. If you were already on a GLP-1 through Part D coverage before July 1 (for diabetes, for example), you cannot switch to the Bridge for the obesity indication separately.

It does not replace your Part D plan. You stay enrolled in your Part D plan for all other prescriptions. The Bridge handles only the Bridge-eligible GLP-1 prescription; everything else continues as before.

The Bridge transitions to the BALANCE Model on January 1, 2028 (the BALANCE Model itself launches in Part D on January 1, 2027, and runs in parallel with the Bridge for 12 months before the Bridge ends).

BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is the permanent Medicare Part D obesity-coverage architecture. The framework is risk-stratified (patients with higher comorbidity loads get easier access and lower copays), uses value-based payment arrangements with manufacturers (lower negotiated prices in exchange for broader coverage), and integrates lifestyle-intervention requirements (nutrition counseling, physical activity coaching) as a coverage condition for certain tiers.

For a patient already on the Bridge as of December 31, 2027, the transition should be straightforward: your eligibility is documented, your prescription history is on file with Humana, and your prescriber writes a renewal under the BALANCE framework. The expected difference is the copay structure (which has not been fully published as of June 2026), the lifestyle-intervention requirements at certain tiers, and the addition of more covered drugs (retatrutide is expected to be eligible once FDA-approved; CagriSema and survodutide may be added depending on their 2026-2027 approval timelines).

The Bridge is best understood as the 18-month bridge that gets patients on the drug while CMS works out the BALANCE Model details.

The Bridge breaks a 20-year exclusion of obesity drugs from Medicare Part D. It is one of the largest single coverage expansions for an obesity therapy in US history.

CMS has not published final estimates for the number of Medicare beneficiaries that will qualify. Independent analyst estimates run between several hundred thousand and several million eligible patients across the 18-month Bridge period, depending on how strictly the BMI-and-condition criteria are interpreted and how quickly prescribers and pharmacies adapt to the new workflow.

Three things will determine whether the Bridge succeeds. The first is the prior-authorization throughput at Humana: a high-volume central processor handling hundreds of thousands of PAs needs to do it fast enough that patients are not waiting weeks for a first fill. The second is the supply side: the Bridge launches the same week that the FDA closes the 503B comment window on excluding semaglutide, tirzepatide, and liraglutide from bulk compounding. Branded supply needs to absorb the demand that compounded supply previously filled. The third is prescriber familiarity: a large share of primary-care physicians have not written GLP-1 prescriptions for Medicare patients before, and the Bridge prior-authorization workflow is new.

What to do this week: if you think you might qualify, call your prescribing physician's office and ask whether they are accepting Bridge prior-authorization requests starting Wednesday July 1. Some practices will be ready on day one; some will take a few weeks. Verify your Part D enrollment is active. Confirm with your pharmacy that they are set up to bill the Bridge BIN/PCN (028918 / MEDDGLP1BR). The first fills will go through during the second week of July; the wider rollout will spread across the back half of 2026.